Latest news

CAMBRIDGE, Mass., Sept. 27, 2022 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (NASDAQ:TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors,

  Monday saw 825 companies set new 52-week lows.

  On Thursday, 1076 companies hit new 52-week lows.

  On Thursday, 94 companies set new 52-week lows.

HC Wainwright & Co. analyst Robert Burns maintains TCR2 Therapeutics (NASDAQ:TCRR) with a Buy and lowers the price target from $19 to $14.

TCR2 Therapeutics (NASDAQ:TCRR) reported quarterly losses of $(0.76) per share. This is a 31.03 percent decrease over losses of $(0.58) per share from the same period last year.

  During Thursday, 849 stocks hit new 52-week lows.

  Wednesday's session saw 784 companies set new 52-week lows.

  On Tuesday, 242 companies hit new 52-week lows.

SVB Leerink cut the price target on TCR2 Therapeutics Inc. (NASDAQ: TCRR) from $7 to $3. TCR2 Therapeutics shares rose 16% to close at $3.19 on Tuesday.